Skip to main content

Dex-CSDH study outcomes published in the New England Journal of Medicine

Outcomes of a trial of Dexamethasone for Chronic Subdural Hematoma has been published in the New England Journal of Medicine, on behalf of the British Neurosurgical Trainee Research Collaborative and Dex-CSDH Trial Collaborators.


Prof P Hutchinson
Professor Peter Hutchinson

Professor of Neurosurgery, University of Cambridge 

Dex-CSDH is a pragmatic, multi-centre, double-blind, phase III randomised, placebo-controlled trial assessing the clinical utility of a tapering 2-week course of dexamethasone following Chronic Subdural Haematoma. The patients were assigned in a 1:1 ratio to receive a 2-week tapering course of oral dexamethasone, starting at 8 mg twice daily, or placebo. The decision to surgically evacuate the hematoma was made by the treating clinician. The primary outcome was a score of 0 to 3, representing a favorable outcome, on the modified Rankin scale at 6 months after randomization; scores range from 0 (no symptoms) to 6 (death).

The results of the trial suggest that among adults with symptomatic chronic subdural hematoma, most of whom had undergone surgery to remove their hematomas during the index admission, treatment with dexamethasone resulted in fewer favorable outcomes and more adverse events than placebo at 6 months, but fewer repeat operations were performed in the dexamethasone group. Dexamethasone was associated with more adverse events than placebo.

For more information visit: N Engl J Med

Published December 31 2020

Latest from CCTU

New clues about irritable bowel syndrome found in the brain

Breakthrough research led by Addenbrooke's Hospital gives IBS patients like Laura Tebbs a better understanding of their condition.

Researchers eye up new gene therapy trial that could reverse hereditary blindness

Restoration of sight from a rare genetic mutation may now become a reality thanks to a prestigious award from the National Institute for Health Research (…

Artificial pancreas trialled for outpatients with type 2 diabetes for first time

An artificial pancreas could soon help people living with type 2 diabetes and who also require kidney dialysis.

All news